Importantly, the top six treatment-specific lncRNAs (Table 7), HCCATS-as1, ADGRL3-as1, BCDIN3D-as1, and RALY-as1, are unexplored and are not known for any activity relevant to cancer progression or drug resistance and hence provide valuable insights into molecules that can be relevant for future studies in this context. This evidence concerns the gene RALY and cancer.